Clarus touts top-line results in phase III testosterone replacement study

Tuesday, September 25, 2012 02:39 PM

Clarus Therapeutics, a Northbrook, Ill.-based privately held biopharmaceutical company focused on oral T replacement products, released top-line results from its ongoing phase III study of CLR-610, a proprietary oral testosterone (T) replacement product.

In this positive-controlled study, data from the 90-day treatment phase demonstrate that 87% of the 141 men treated with CLR-610 achieved average serum T levels (C-avg) in the normal range (300-1,000ng/dL), the study's primary efficacy endpoint. The C-avg in men treated with CLR-610 was 624 ng/dL. This compares to the 80% of the 146 men in the T-gel comparison arm who achieved C-avg in the normal range. The C-avg in men treated with the T-gel comparison arm was 480 ng/dL.

"We are particularly excited about the significant number of men receiving CLR-610 who achieved normal T levels in this study," said Bela S. Denes, M.D., chief medical officer of Clarus. "Market research shows that men currently being treated for low T with transdermal or injectable products would overwhelmingly prefer an oral option. Thus, we believe CLR-610 will have strong appeal."

The study enrolled 325 men with low serum T (less than 300ng/dL) in 25 sites in the U.S. and five sites in Germany. Men were randomly assigned to receive CLR-610 or T-gel. Primary endpoint of the ongoing study is the percentage of men who achieve normal serum T levels after administration of CLR-610 for 90 days. At least 75% of men on day 90 must had an average serum T in the normal range to meet current FDA efficacy guidance for T replacement products.

Consistent with phase II results, there was no evidence of liver toxicity in men treated with CLR-610 or T-gel.

"The results observed thus far with CLR-610 are very encouraging and the feedback we received from trial participants at UCLA has been extremely positive," added Ronald S. Swerdloff, M.D., chief of the division of endocrinology, department of medicine at the Harbor-UCLA Medical Center and the principal investigator at the LA Biomedical Research Institute on the phase III study. "The convenience of an oral T replacement option is one that I believe patients and their healthcare providers will embrace."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs